Middle East News 21 February 2026

BAE Systems share price jumps nearly 8% as Middle East conflict lifts FTSE defence stock
···

BAE Systems share price jumps nearly 8% as Middle East conflict lifts FTSE defence stock

BAE Systems shares rose 7.9% to 2,278 pence in early London trading Monday, nearing a 52-week high after a new buyback filing. The move followed heightened Middle East tensions and rising oil prices, with Brent crude up 6.4% to $77.57. BAE reported buying 103,006 shares for cancellation at an average price of 2,126.09 pence. The stock ended Friday at 2,112 pence.
March 2, 2026
Qatar National Bank stock ends weak week on Qatar Stock Exchange as Iran risk hangs over Sunday open
···

Qatar National Bank stock ends weak week on Qatar Stock Exchange as Iran risk hangs over Sunday open

Qatar National Bank closed at 19.68 riyals Thursday, down 3.5% for the week but up 5.5% in 2026. The QE Index dropped 2.5% to 11,229.06 as market value fell to 669.4 billion riyals. Traded value slid 11.5% to 2.03 billion riyals, with QNBK leading volumes. Regional markets declined amid U.S.-Iran tensions and talk of possible U.S. military action.
February 21, 2026

Stock Market Today

  • Aroa Biosurgery Advances in US$3 Billion Woundcare Market with Innovative Myriad Device
    May 26, 2026, 4:20 PM EDT. Aroa Biosurgery (ASX:ARX) is expanding in the US woundcare market, valued at over US$3 billion, with its flagship Myriad product. The company, based in Auckland, leverages unique sheep-derived biomaterials to improve patient outcomes while lowering hospital costs. Despite stiff competition and reimbursement challenges, Aroa has reported two consecutive years of positive earnings. It focuses on robust clinical evidence, including large-scale, randomized studies, to prove the efficacy of its devices in treating complex wounds and diabetic foot ulcers. CEO Brian Ward highlights the economic benefit of reducing repeat procedures, aligning clinical success with hospital budget restraints. Aroa's diversified portfolio also includes Endoform and Symphony, while it licenses TELA Bio for additional surgical applications.